Last reviewed · How we verify
CORN OIL
CORN OIL is a marketed product without specified primary indications or revenue data, positioned in a competitive landscape with a key composition patent expiring in 2028. The key strength of CORN OIL lies in its established market presence, leveraging its current approval status. The primary risk is the potential increase in competition post-2028, as the key patent expiry may allow generic entries.
At a glance
| Generic name | CORN OIL |
|---|---|
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Effects of Probiotics on Respiratory Tract Infections in Children: A Randomized, Placebo-Controlled Interventional Study (PHASE2)
- FAST for DM - Fatty Acid Supplementation Trial (FAST) for Dermatomyositis (DM) (PHASE2)
- Heart & Health Study (NA)
- Treatment of Severe Acute Malnutrition in Children 6 to 59 Months Old With Standard Ready To Use Therapeutic Food Compared to a Newly Formulated Lipid Optimized Ready To Use Therapeutic Food (NA)
- Effects of Ketone Ester Consumption on Exercise Tolerance and Cardiac Function (NA)
- Leucine Requirements During Pregnancy (NA)
- ALA-enriched Nutrition for Prevention of Cognitive Decline in APOE4 Older Adults (PHASE2)
- The Effect of Probiotics on Gut Microbiota Changes in Healthy Chinese Adults During Short-Term European Travel: A Randomised, Double-Blind, Placebo-Controlled Clinical Trial (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CORN OIL CI brief — competitive landscape report
- CORN OIL updates RSS · CI watch RSS